Compare PDYN & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDYN | TRDA |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 292.0M | 274.5M |
| IPO Year | N/A | 2021 |
| Metric | PDYN | TRDA |
|---|---|---|
| Price | $7.11 | $6.85 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $9.67 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 2.0M | 272.4K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $25,421,000.00 |
| Revenue This Year | $384.48 | $39.97 |
| Revenue Next Year | $63.16 | $50.80 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.14 | $4.93 |
| 52 Week High | $12.79 | $16.45 |
| Indicator | PDYN | TRDA |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 44.91 |
| Support Level | $5.89 | $5.75 |
| Resistance Level | $7.77 | $7.02 |
| Average True Range (ATR) | 0.79 | 0.46 |
| MACD | -0.14 | 0.25 |
| Stochastic Oscillator | 36.46 | 80.80 |
Palladyne AI Corp is a software company focused on autonomy for robotic systems and solutions. Its artificial intelligence and machine learning software seeks to revolutionize the capabilities of robots, enabling them to observe, learn, reason, and act in structured and unstructured environments. AI and ML software platform of the company empowers robots to perceive variations or changes in the real-world environment, enabling them to autonomously maneuver and manipulate objects accurately in response. Palladyne AI software has wide application, including in industries such as automotive, aviation, construction, defense, general manufacturing, infrastructure inspection, logistics and warehousing.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.